본문 바로가기
KERD
논문KCI 등재

Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence

Kim Eu Suk|Choi Seong Jin
대한감염학회 (The Korean Society Of Infectious Diseases)|2024.06|Infection and Chemotherapy|제56권 제2호|pp. 171-187|DOI 10.3947/ic.2024.0055

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Acinetobacter baumanni complexMultidrug resistant organisms
주제분류내과학

초록

Carbapenem-resistant Acinetobacter baumannii complex (CRAB) poses a significant global health challenge owing to its resistance to multiple antibiotics and limited treatment options. Polymyxin-based therapies have been widely used to treat CRAB infections; however, they are associated with high mortality rates and common adverse events such as nephrotoxicity. Recent developments include numerous observational studies and randomized clinical trials investigating antibiotic combinations, repurposing existing antibiotics, and the development of novel agents. Consequently, recommendations for treating CRAB are undergoing significant changes. The importance of colistin is decreasing, and the role of sulbactam, which exhibits direct antibacterial activity against A. baumannii complex, is being reassessed. High-dose ampicillin-sulbactam-based combination therapies, as well as combinations of sulbactam and durlobactam, which prevent the hydrolysis of sulbactam and binds to penicillin-binding protein 2, have shown promising results. This review introduces recent advancements in CRAB infection treatment based on clinical trial data, highlighting the need for optimized treatment protocols and comprehensive clinical trials to combat the evolving threat of CRAB effectively.

Abstract

Carbapenem-resistant Acinetobacter baumannii complex (CRAB) poses a significant global health challenge owing to its resistance to multiple antibiotics and limited treatment options. Polymyxin-based therapies have been widely used to treat CRAB infections; however, they are associated with high mortality rates and common adverse events such as nephrotoxicity. Recent developments include numerous observational studies and randomized clinical trials investigating antibiotic combinations, repurposing existing antibiotics, and the development of novel agents. Consequently, recommendations for treating CRAB are undergoing significant changes. The importance of colistin is decreasing, and the role of sulbactam, which exhibits direct antibacterial activity against A. baumannii complex, is being reassessed. High-dose ampicillin-sulbactam-based combination therapies, as well as combinations of sulbactam and durlobactam, which prevent the hydrolysis of sulbactam and binds to penicillin-binding protein 2, have shown promising results. This review introduces recent advancements in CRAB infection treatment based on clinical trial data, highlighting the need for optimized treatment protocols and comprehensive clinical trials to combat the evolving threat of CRAB effectively.

참고문헌 (135)

  1. Antimicrobial Resistance Collaborators, "Global burden of bacterial antimicrobial resistance in 2019 : a systematic analysis", Lancet, 399, pp.629~655 (2022)
  2. Tacconelli E, "Discovery, research, and development of new antibiotics : the WHO priority list of antibiotic-resistant bacteria and tuberculosis", Lancet Infect Dis, 18, pp.318~327 (2018)
  3. Brisou J, "Studies on bacterial taxonomy. X. The revision of species under Acromobacter group", Ann Inst Pasteur(Paris), 86, pp.722~728 (1954)
  4. Baumann P, "A study of the Moraxella group. II. Oxidative-negative species(genus Acinetobacter)", J Bacteriol, 95, pp.1520~1541 (1968)
  5. Howard A, "Acinetobacter baumannii : an emerging opportunistic pathogen", Virulence, 3, pp.243~250 (2012)
  6. Qin J, "Precise species identification for Acinetobacter : a genome-based study with description of two novel Acinetobacter species", mSystems, 6, pp.e0023721~ (2021)
  7. Touchon M, "The genomic diversification of the whole Acinetobacter genus : origins, mechanisms, and consequences", Genome Biol Evol, 6, pp.2866~2882 (2014)
  8. Towner KJ, "Acinetobacter : an old friend, but a new enemy", J Hosp Infect, 73, pp.355~363 (2009)
  9. Vijayakumar S, "Accurate identification of clinically important Acinetobacter spp. : an update", Future Sci OA, 5, pp.FSO395~ (2019)
  10. Turton JF, "Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter : evidence for emerging species", J Clin Microbiol, 48, pp.1445~1449 (2010)
  11. Wisplinghoff H, "Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States", J Infect, 64, pp.282~290 (2012)
  12. Akeda Y, "Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast Asia", Microbiol Immunol, 65, pp.229~237 (2021)
  13. Jeong S, "Identification of Acinetobacter species using matrix-assisted laser desorption ionization-time of flight mass spectrometry", Ann Lab Med, 36, pp.325~334 (2016)
  14. Seok H, "What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea", J Glob Antimicrob Resist, 24, pp.429~439 (2021)
  15. Magill SS, "Multistate point-prevalence survey of health care-associated infections", N Engl J Med, 370, pp.1198~1208 (2014)
  16. Gales AC, "Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates : results from the SENTRY antimicrobial surveillance program(1997-2016)", Open Forum Infect Dis, 6(Suppl 1), pp.S34~S46 (2019)
  17. Seifert H, "Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes(2016-2018)", J Glob Antimicrob Resist, 31, pp.82~89 (2022)
  18. Mugnier PD, "Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii", Emerg Infect Dis, 16, pp.35~40 (2010)
  19. Castanheira M, "Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex", Clin Infect Dis, 76(Suppl 2), pp.S166~S178 (2023)
  20. Ramirez MS, "Carbapenemases : Transforming Acinetobacter baumannii into a yet more dangerous menace", Biomolecules, 10, pp.720~ (2020)
  21. Kim Y, "Clonal change of blaSIM-1-carrying Acinetobacter spp. from 2003 to 2008 in the hospital where it was initially discovered", Microb Drug Resist, 19, pp.37~41 (2013)
  22. Choi JY, "Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013 : results from the Korean Nosocomial Infections Surveillance System(KONIS)", J Hosp Infect, 92, pp.363~371 (2016)
  23. Song KH, "Clinical and economic burden of bacteremia due to multidrug-resistant organisms in Korea : a prospective case control study", J Glob Antimicrob Resist, 31, pp.379~385 (2022)
  24. Kim T, "Early intravenous colistin therapy as a favorable prognostic factor for 28-day mortality in patients with CRAB bacteremia : a multicenter propensity score-matching analysis", J Korean Med Sci, 34, pp.e256~ (2019)
  25. Son HJ, "Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia", Open Forum Infect Dis, 7, pp.ofaa378~ (2020)
  26. Lee CM, "Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia", J Glob Antimicrob Resist, 31, pp.45~51 (2022)
  27. Lee CM, "Different clinical characteristics and impact of carbapenem-resistance on outcomes between Acinetobacter baumannii and Pseudomonas aeruginosa bacteraemia : a prospective observational study", Sci Rep, 12, pp.8527~ (2022)
  28. Park SY, "Risk factors for mortality in patients with Acinetobacter baumannii bacteremia", Infect Chemother, 45, pp.325~330 (2013)
  29. Tamma PD, "Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections", Clin Infect Dis, pp.ciad428~ (2023)
  30. Paul M, "European Society of Clinical Microbiology and Infectious Diseases(ESCMID)guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli(endorsed by European society of intensive care medicine)", Clin Microbiol Infect, 28, pp.521~547 (2022)
  31. Shields RK, "Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections", Clin Infect Dis, 76(Suppl 2), pp.S179~S193 (2023)
  32. Koyama Y, "A new antibiotic"colistin"produced by spore-forming soil bacteria", J Antibiot, 3, pp.457~458 (1950)
  33. Landman D, "Polymyxins revisited", Clin Microbiol Rev, 21, pp.449~465 (2008)
  34. Li Z, "Polymyxins : mode of action", Adv Exp Med Biol, 1145, pp.37~54 (2019)
  35. Manioglu S, "Antibiotic polymyxin arranges lipopolysaccharide into crystalline structures to solidify the bacterial membrane", Nat Commun, 13, pp.6195~ (2022)
  36. Grégoire N, "Clinical Pharmacokinetics and Pharmacodynamics of Colistin", Clin Pharmacokinet, 56, pp.1441~1460 (2017)
  37. Falagas ME, "Colistin : the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections", Clin Infect Dis, 40, pp.1333~1341 (2005)
  38. Dijkmans AC, "Colistin : revival of an old polymyxin antibiotic", Ther Drug Monit, 37, pp.419~427 (2015)
  39. Talbot GH, "Bad bugs need drugs : an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America", Clin Infect Dis, 42, pp.657~668 (2006)
  40. Clinical and Laboratory Standards Institute (CLSI), "Perforance standards for antimicrobial susceptibility tests" (2020), CLSI
  41. Bostanghadiri N, "Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii : a systematic review and meta-analysis", Antimicrob Resist Infect Control, 13, pp.24~ (2024)
  42. Kim D, "Major bloodstream infection-causing bacterial pathogens and their antimicrobial resistance in South Korea, 2017-2019 : phase I report from Kor-GLASS", Front Microbiol, 12, pp.799084~ (2022)
  43. Landersdorfer CB, "Substantial targeting advantage achieved by pulmonary administration of colistin methanesulfonate in a large-animal model", Antimicrob Agents Chemother, 61, pp.e01934-16~ (2016)
  44. Eljaaly K, "Colistin nephrotoxicity : meta-analysis of randomized controlled trials", Open Forum Infect Dis, 8, pp.ofab026~ (2021)
  45. Paul M, "Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria : an open-label, randomised controlled trial", Lancet Infect Dis, 18, pp.391~400 (2018)
  46. Kaye KS, "Colistin monotherapy versus combination therapy for carbapenem-resistant organisms", NEJM Evid, 2 (2023)[DOI]
  47. Lenhard JR, "High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a Hollow-Fiber infection model", Antimicrob Agents Chemother, 61, pp.e01268-16~ (2017)
  48. Lenhard JR, "Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity", J Antimicrob Chemother, 72, pp.1415~1420 (2017)
  49. Qureshi ZA, "Colistin-resistant Acinetobacter baumannii : beyond carbapenem resistance", Clin Infect Dis, 60, pp.1295~1303 (2015)
  50. Heil EL, "Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients", J Antimicrob Chemother, 78, pp.1034~1040 (2023)
  51. Sirijatuphat R, "Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections", Antimicrob Agents Chemother, 58, pp.5598~5601 (2014)
  52. Durante-Mangoni E, "Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii : a multicenter, randomized clinical trial", Clin Infect Dis, 57, pp.349~358 (2013)
  53. Aydemir H, "Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia", Epidemiol Infect, 141, pp.1214~1222 (2013)
  54. Park HJ, "Colistin monotherapy versus colistin", rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii : A randomised controlled trial, 2019, pp.17, 66~71
  55. Imberti R, "Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration", Chest, 138, pp.1333~1339 (2010)
  56. Rattanaumpawan P, "Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria", J Antimicrob Chemother, 65, pp.2645~2649 (2010)
  57. Rello J, "Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults : a position paper from the European Society of Clinical Microbiology and Infectious Diseases", Clin Microbiol Infect, 23, pp.629~639 (2017)
  58. Papp-Wallace KM, "Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3", Antimicrob Agents Chemother, 56, pp.5687~5692 (2012)
  59. Penwell WF, "Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii", Antimicrob Agents Chemother, 59, pp.1680~1689 (2015)
  60. Lee YL, "Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region : results from the Antimicrobial Testing Leadership and Surveillance(ATLAS)program, 2012-2019", Int J Infect Dis, 127, pp.48~55 (2023)
  61. Rodríguez-Hernández MJ, "Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains", J Antimicrob Chemother, 47, pp.479~482 (2001)
  62. Betrosian AP, "High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii", Scand J Infect Dis, 39, pp.38~43 (2007)
  63. Betrosian AP, "Efficacy and safety of high-dose ampicillin", sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, 2008, pp.56, 432~436
  64. Khalili H, "Meropenem", colistin versus meropenem, J Comp Eff Res, pp.2018, 7[DOI]
  65. Mosaed R, "Interim study : comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin", sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter, 2018, pp.17(Suppl2), 206~213
  66. Pourheidar E, "Comparison of intravenous ampicillin-sulbactam plus nebulized colistin with intravenous colistin plus nebulized colistin in treatment of ventilator associated pneumonia caused by multi drug resistant Acinetobacter baumannii : randomized open label trial", Iran J Pharm Res, 18(Suppl1), pp.269~281 (2019)
  67. Makris D, "Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment : an open-label prospective study", Indian J Crit Care Med, 22, pp.67~77 (2018)
  68. Jung SY, "Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients : a systemic review and Bayesian network meta-analysis", Crit Care, 21, pp.319~ (2017)
  69. Chen H, "Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection : a systematic review and meta-analysis", J Infect Chemother, 23, pp.278~285 (2017)
  70. Kengkla K, "Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections : a systematic review and network meta-analysis", J Antimicrob Chemother, 73, pp.22~32 (2018)
  71. Liu J, "Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections : a systematic review and network meta-analysis", J Glob Antimicrob Resist, 24, pp.136~147 (2021)
  72. Chu H, "Sulbactam-based therapy for Acinetobacter baumannii infection : a systematic review and meta-analysis", Braz J Infect Dis, 17, pp.389~394 (2013)
  73. Jaruratanasirikul S, "Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii", Eur J Pharm Sci, 136, pp.104940~ (2019)
  74. Valcke YJ, "Penetration of ampicillin and sulbactam in the lower airways during respiratory infections", Antimicrob Agents Chemother, 34, pp.958~962 (1990)
  75. Cruciani M, "Pharmacokinetics of antimicrobial agents in the respiratory tract", Zentralbl Bakteriol, 284, pp.1~31 (1996)
  76. Onita T, "Pulmonary pharmacokinetic and pharmacodynamic evaluation of ampicillin", sulbactam regimens for pneumonia caused by various bacteria, including Acinetobacter baumannii, 2023, pp.12, 303~
  77. Krizova L, "TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii", J Antimicrob Chemother, 68, pp.2786~2791 (2013)
  78. "Efficacy and safety of colistin plus high dose ampicillin/sulbactam vs. colistin monotherapy for the treatment of carbapenem resistant Acinetobacter baumannii (CRAB) bacteremia: a multicenter, open-label, randomized controlled trial"[URL]
  79. Kalil AC, "Management of adults with hospital-acquired and ventilator-associated pneumonia : 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis, 63, pp.e61~e111 (2016)
  80. Torres A, "International ERS", ESICM, ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia : Guidelines for the management of hospital-acquired pneumonia(HAP), pp.ventilator-associated pneumonia(VAP)of the European Respiratory Society(ERS), European Society of Intensive Care Medicine(ESICM), European Society of Clinical Microbiology and Infectious Diseases(ESCMID)and Asociación Latinoamericana del Tórax(ALAT), Eur Respir J[DOI]
  81. Freire AT, "Comparison of tigecycline with imipenem", cilastatin for the treatment of hospital-acquired pneumonia, 2010, pp.68, 140~151
  82. Muralidharan G, "Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects", Antimicrob Agents Chemother, 49, pp.220~229 (2005)
  83. Stein GE, "Tigecycline : an update", Diagn Microbiol Infect Dis, 75, pp.331~336 (2013)
  84. Liang CA, "Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii", Clin Microbiol Infect, 24, pp.908~ (2018)
  85. Liou BH, "Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure", Antimicrob Agents Chemother, 59, pp.3637~3640 (2015)
  86. Niu T, "Comparison of tigecycline or cefoperazone", sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii, 2019, pp.8, 52~
  87. Amat T, "The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii", Clin Microbiol Infect, 24, pp.630~634 (2018)
  88. Zha L, "Effectiveness and safety of high dose tigecycline for the treatment of severe infections : a systematic review and meta-analysis", Adv Ther, 37, pp.1049~1064 (2020)
  89. Ramirez J, "Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia", Antimicrob Agents Chemother, 57, pp.1756~1762 (2013)
  90. De Pascale G, "High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria", Crit Care, 18, pp.R90~ (2014)
  91. Maderazo EG, "Activity of minocycline against Acinetobacter calcoaceticus var. anitratus(syn. Herellea vaginicola)and Serratia marcescens", Antimicrob Agents Chemother, 8, pp.54~57 (1975)
  92. Chopra S, "Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii", J Antimicrob Chemother, 65, pp.2598~2601 (2010)
  93. Flamm RK, "In Vitro activity of minocycline against U. S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex : results from the SENTRY antimicrobial surveillance program, 2014 to 2018", Antimicrob Agents Chemother, 63, pp.e01154-19~ (2019)
  94. Goff DA, "Bad bugs need old drugs : a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections", Clin Infect Di, 59(Suppl 6), pp.S381~S387 (2014)
  95. Pogue JM, "Carbapenem-resistance in Gram-negative bacilli and intravenous minocycline : an antimicrobial stewardship approach at the Detroit Medical Center", Clin Infect Dis, 59(Suppl 6), pp.S388~S393 (2014)
  96. "Efficacy of colistin monotherapy versus colistin plus minocycline for carbapenem-resistant A. baumannii infection"[URL]
  97. Alosaimy S, "Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii", Microbiol Spectr, 10, pp.e0047922~ (2022)
  98. Jackson MNW, "Combination eravacycline therapy for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii in patients with COVID-19 : a case series", Pharmacotherapy, 44, pp.301~307 (2024)
  99. Scott CJ, "Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant(DTR)Acinetobacter baumannii", Ann Pharmacother, 56, pp.1299~1307 (2022)
  100. McCreary EK, "New perspectives on antimicrobial agents : cefiderocol", Antimicrob Agents Chemother, 65, pp.e0217120~ (2021)
  101. Ito A, "In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria", Antimicrob Agents Chemother, 62, pp.e01454-17~ (2017)
  102. Syed YY, "Cefiderocol : a review in serious Gram-negative bacterial infections", Drugs, 81, pp.1559~1571 (2021)
  103. Hackel MA, "In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016", Antimicrob Agents Chemother, 62, pp.e01968-17~ (2018)
  104. Hackel MA, "In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates(SIDERO-WT-2014 Study)", Antimicrob Agents Chemother, 61, pp.e00093-17~ (2017)
  105. Karlowsky JA, "In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016 : SIDERO-WT-2015", Int J Antimicrob Agents, 53, pp.456~466 (2019)
  106. Kazmierczak KM, "In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase-and metallo-β-lactamase-producing isolates(SIDERO-WT-2014 Study)", Int J Antimicrob Agents, 53, pp.177~184 (2019)
  107. Portsmouth S, "Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens : a phase 2, randomised, double-blind, non-inferiority trial", Lancet Infect Dis, 18, pp.1319~1328 (2018)
  108. Wunderink RG, "Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia(APEKS-NP) : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Infect Dis, 21, pp.213~225 (2021)
  109. Bassetti M, "Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria(CREDIBLE-CR) : a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial", Lancet Infect Dis, 21, pp.226~240 (2021)
  110. Falcone M, "Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii", Antimicrob Agents Chemother, 66, pp.e0214221~ (2022)
  111. Pascale R, "Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic : a multicentre cohort study", JAC Antimicrob Resist, 3, pp.dlab174~ (2021)
  112. Simner PJ, "Potential of inaccurate cefiderocol susceptibility results : a CLSI AST subcommittee advisory", J Clin Microbiol, 61, pp.e0160022~ (2023)
  113. Wright H, "Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection : Study protocol(the GAME CHANGER trial) : study protocol for an open-label, randomised controlled trial", Trials, 22(1), pp.889~ (2021)
  114. "RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI (GAMECHANGER)"[URL]
  115. Durand-Réville TF, "ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii", Nat Microbiol, 2, pp.17104~ (2017)
  116. Karlowsky JA, "In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021", Antimicrob Agents Chemother, 66, pp.e0078122~ (2022)
  117. Kaye KS, "Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex : a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial(ATTACK)", Lancet Infect Dis, 23, pp.1072~1084 (2023)
  118. McLeod SM, "Sulbactam-durlobactam : a β-lactam", β-lactamase inhibitor combination targeting Acinetobacter baumannii, 2024, ~
  119. Seifert H, "In vitro activity of sulbactam", durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii, 2020, pp.75, 2616~2621
  120. Fouad A, "In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales", J Antimicrob Chemother, 78, pp.2801~2809 (2023)
  121. McLeod SM, "Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel β-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii", Antimicrob Agents Chemother, 62, pp.e01576-17~ (2018)
  122. Moussa SH, "Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii", Antimicrob Agents Chemother, 67, pp.e0066523~ (2023)
  123. Zampaloni C, "A novel antibiotic class targeting the lipopolysaccharide transporter", Nature, 625, pp.566~571 (2024)
  124. Park J, "Gold nanoparticle-DNA aptamer-assisted delivery of antimicrobial peptide effectively inhibits Acinetobacter baumannii infection in mice", J Microbiol, 60, pp.128~136 (2022)
  125. Park HJ, "Bactericidal activities and action mechanism of the novel antimicrobial peptide Hylin a1 and its analog peptides against Acinetobacter baumannii infection", Eur J Pharm Sci, 175, pp.106205~ (2022)
  126. Luo X, "Identification of the scorpion venom-derived antimicrobial peptide Hp1404 as a new antimicrobial agent against carbapenem-resistant Acinetobacter baumannii", Microb Pathog, 157, pp.104960~ (2021)
  127. Gordillo Altamirano FL, "Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study", EBioMedicine, 80, pp.104045~ (2022)
  128. Leshkasheli L, "Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia", J Glob Antimicrob Resist, 19, pp.255~261 (2019)
  129. Hua Y, "Phage therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant Acinetobacter baumannii in Mice", Front Microbiol, 8, pp.2659~ (2018)
  130. Jeon J, "Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia", BMC Microbiol, 19, pp.70~ (2019)
  131. Regeimbal JM, "Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections", Antimicrob Agents Chemother, 60, pp.5806~5816 (2016)
  132. Nir-Paz R, "Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination", Clin Infect Dis, 69, pp.2015~2018 (2019)
  133. Schooley RT, "Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection", Antimicrob Agents Chemother, 61, pp.e00954-17~ (2017)
  134. Lood R, "Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model", Antimicrob Agents Chemother, 59, pp.1983~1991 (2015)
  135. Jun SH, "Clonal change of carbapenem-resistant Acinetobacter baumannii isolates in a Korean hospital", Infect Genet Evol, 93, pp.104935~ (2021)

관련 논문AI추천

High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii권선중, 정인범, Do Yeon Jo, Ji Woong Son, Moon Jun Na대한중환자의학회 · Acute and Critical Care2016 · 제31권 제4호Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens이창섭, Yohei Doi대한감염학회 · Infection and Chemotherapy2014 · 제46권 제3호Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?Changpradub Dhitiwat, Juntanawiwat Piraporn, Nulsopapon Parnrada, Saelim Weerayuth, Santimaleeworagun Wichai, Sudaluck Thunyaharn대한감염학회 · Infection and Chemotherapy2021 · 제53권 제1호In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates어영, 송원근, 신희봉, 용동은, 이경원, 이혁민, 정석훈, 홍성근, Kyung Ho Roh대한진단검사의학회 · Annals of Laboratory Medicine2016 · 제36권 제2호In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii박건, 강성호, 김춘미, 문대수, 박균철, 장숙진, 정석훈, 최인선, 최지애대한진단검사의학회 · Annals of Laboratory Medicine2016 · 제36권 제2호The Mortality of Colistin Monotherapy vs. Colistin-Sulbactam for Carbapenem-Resistant Acinetobacter baumannii Pneumonia: A Propensity Score AnalysisChangpradub Dhitiwat, Cheh-Oh Nadia, Santimaleeworagun Wichai, Ungthammakhun Chutchawan대한감염학회 · Infection and Chemotherapy2025 · 제57권 제1호

이 간행물의 다른 논문 (15건)

Tick-Borne Rickettsiosis and Tsutsugamushi Disease Recorded in 313Kang Jae-Seung, Chung Moon-Hyun, Lee Jin-Soopp. 159-170Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition백지현, Lee Dong-Gun, Kwon Ki Tae, Park Wan Beom, Choi Jun Yong, Yeom Joon-Sup, Han Sang Hoon, Lee Jin-Soo, Chin Bum Sik, Choi Young Hwa, Choi Won Suk, Lee Hyo-Jin, 추은주, Kim Woo Joo, Choi Hee-Jung, Choi Jung-Hyun, Cheong Hee Jin, 이미숙, 송준영pp. 188-203Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Seoul, KoreaChoe Young June, 권민수, Son Euncheol, Sim JiWoo, Hwang Eun Jin, Lee Young Hwapp. 204-212Six-Year Study on Cutaneous Leishmaniasis in Al-Muthanna, Iraq: Molecular Identification Using ITS1 Gene SequencingFlaih Mohammed H., Hussein Khwam R., Alwaily Enas R., Hafedh Alyaa A.pp. 213-221Carbapenem-resistant Acinetobacter baumannii Outbreak in a COVID-19 Isolation Ward and Successful Outbreak Control with Infection Control MeasuresKim Chang Hyup, Kwon Oh Mi, You Eun Ju, 구남수, 김진남, 이혁민, Yeom Joon Sup, Choi Jun Yong, Lee Jung Ah, Ahn Jin Young, Jeong Su Jin, Kim Jung Ho, Lee Ki Hyunpp. 222-229
원문 보기